1. Wahl RL, Zasadny K, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39(8 Suppl):21S–7S.
2. Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy. J Nucl Med 2002;43(9):1245–53.
3. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45(10):1725–33.
4. Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36(7):1138–46.
5. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med 1998;39(10):1746–51.